Palvella Therapeutics (PVLA) Other Accumulated Expenses (2013 - 2026)
Palvella Therapeutics (PVLA) reported Other Accumulated Expenses of $960000.0 for Q1 2026, up 16.36% year-over-year from $825000.0 in Q1 2025, and down 20.0% on a QoQ basis from $1.2 million in Q4 2025.
Palvella Therapeutics (PVLA) has 14 years of Other Accumulated Expenses data on file, last reported at $960000.0 in Q1 2026.
- Quarterly Other Accumulated Expenses rose 16.36% year-over-year to $960000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $960000.0 (up 16.36% YoY) and the FY2025 annual result came in at $1.2 million, up 197.03% from the prior year.
- Other Accumulated Expenses declined to $960000.0 in Q1 2026 per PVLA's latest filing, from $1.2 million in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $1.2 million in Q4 2025 and bottomed at $120000.0 in Q4 2023.
- The 5-year median for Other Accumulated Expenses is $610000.0 (2022), against an average of $696294.1.
- The widest annual swing landed in 2022, when Other Accumulated Expenses soared 252.6%; it then slumped 75.16% in 2023.
- Tracing PVLA's Other Accumulated Expenses over 5 years: stood at $483000.0 in 2022, then tumbled by 75.16% to $120000.0 in 2023, then surged by 236.67% to $404000.0 in 2024, then jumped by 197.03% to $1.2 million in 2025, then fell by 20.0% to $960000.0 in 2026.
- Per Business Quant, the three latest PVLA Other Accumulated Expenses figures stand at $960000.0 (Q1 2026), $1.2 million (Q4 2025), and $1.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 960,000.00 |
| Dec 31, 2025 | 1.20 Mn |
| Sep 30, 2025 | 1.05 Mn |
| Jun 30, 2025 | 925,000.00 |
| Mar 31, 2025 | 825,000.00 |
| Dec 31, 2024 | 404,000.00 |
| Sep 30, 2024 | 1.03 Mn |
| Jun 30, 2024 | 1.01 Mn |
| Mar 31, 2024 | 335,000.00 |
| Dec 31, 2023 | 120,000.00 |
| Sep 30, 2023 | 575,000.00 |
| Jun 30, 2023 | 497,000.00 |
| Mar 31, 2023 | 590,000.00 |
| Dec 31, 2022 | 483,000.00 |
| Sep 30, 2022 | 581,000.00 |
| Jun 30, 2022 | 610,000.00 |
| Mar 31, 2022 | 637,000.00 |
| Dec 31, 2021 | 393,000.00 |
| Sep 30, 2021 | 222,000.00 |
| Jun 30, 2021 | 173,000.00 |
| Mar 31, 2021 | 336,000.00 |
| Dec 31, 2020 | 347,000.00 |
| Sep 30, 2020 | 664,000.00 |
| Jun 30, 2020 | 350,000.00 |
| Mar 31, 2020 | 512,000.00 |
| Dec 31, 2019 | 458,000.00 |
| Sep 30, 2019 | 1.04 Mn |
| Jun 30, 2019 | 1.07 Mn |
| Mar 31, 2019 | 1.34 Mn |
| Dec 31, 2018 | 945,000.00 |
| Sep 30, 2018 | 772,000.00 |
| Jun 30, 2018 | 1.78 Mn |
| Mar 31, 2018 | 2.53 Mn |
| Dec 31, 2017 | 1.31 Mn |
| Dec 31, 2016 | 158,000.00 |
| Sep 30, 2015 | 65,714.00 |
| Jun 30, 2015 | 153,082.00 |
| Mar 31, 2015 | 274,255.00 |
| Dec 31, 2014 | 242,755.00 |
| Dec 31, 2013 | 12,389.00 |